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Identification of causal genes
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A B S T R A C T
The present article summarizes recent developments in the characterization of genetic predisposition to color-
ectal cancer (CRC). The main themes covered include new hereditary CRC and polyposis syndromes, non-CRC
hereditary cancer genes found mutated in CRC patients, strategies used to identify novel causal genes, and
review of candidate genes that have been proposed to predispose to CRC and/or colonic polyposis. We provide
an overview of newly described genes and syndromes associated with predisposition to CRC and polyposis,
including: polymerase proofreading-associated polyposis, NTHL1-associated polyposis, mismatch repair gene
biallelic inactivation-related adenomatous polyposis (including MSH3- and MLH3-associated polyposes),
GREM1-associated mixed polyposis, RNF43-associated serrated polyposis, and RPS20 mutations as a rare cause
of hereditary nonpolyposis CRC. The implementation of next generation sequencing approaches for genetic
testing has exposed the presence of pathogenic germline variants in genes associated with hereditary cancer
syndromes not traditionally linked to CRC, which may have an impact on genetic testing, counseling and sur-
veillance. The identification of new hereditary CRC and polyposis genes has not deemed an easy endeavor, even
though known CRC-related genes explain a small proportion of the estimated familial risk. Whole-genome se-
quencing may offer a technology for increasing this proportion, particularly if applied on pedigree data allowing
linkage type of analysis. The final section critically surveys the large number of candidate genes that have been
recently proposed for CRC predisposition.
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Genetic predisposition, due to pathogenic germline variants in high
risk cancer genes, has been implicated in 2–8% of all CRCs (and 1 in 5
of those diagnosed at age< 50) (AlDubayan et al., 2018; DeRycke
et al., 2017; Mork et al., 2015; Pearlman et al., 2017; Stoffel et al.,
2018; Yurgelun et al., 2017). This genetic predisposition to CRC has
been classically associated with germline mutations or epimutations in
the DNA mismatch repair (MMR) genes MLH1, MSH2, MSH6 and PMS2
for nonpolyposis cases, and in APC and MUTYH (recessive inheritance)
for adenomatous colonic polyposis. Other -less frequent- CRC predis-
posing syndromes, characterized by the presence of hamartomatous
polyps, are caused by mutations in SMAD4, BMPR1A, STK11 and PTEN
(Valle, 2014). Despite this knowledge, much of the genetic predis-
position to CRC and polyposis is still unexplained. In the last years,
important efforts have been invested to identify new causal genes that
explain this predisposition, as the identification of a germline patho-
genic mutation that causes the increased risk and aggregation of CRC in
a family has clear consequences in the clinical management of its
members. The following article provides an overview of the newly
identified genes and syndromes associated with predisposition to CRC
and polyposis, and assesses the involvement of a priori non-CRC her-
editary cancer genes in CRC predisposition. Likewise, recent and effi-
cient tools for causal gene identification are surveyed, and a final sec-
tion reviews the candidate genes proposed in the last years.
2. New hereditary colorectal cancer (CRC) and polyposis
syndromes
2.1. Polymerase proofreading-associated polyposis
The evolution of a normal cell into a cancerous cell has been re-
garded for long as a result of multiple changes in nucleic acids se-
quences, chromosomal rearrangements and aneuploidy. This genome
instability permits to acquire biological capacities such as sustaining
proliferative signaling, evading growth suppressors, resisting cell death,
enabling replicative immortality, inducing angiogenesis, and activating
invasion and metastasis (Hanahan and Weinberg, 2011). Alterations in
replicative DNA polymerases increase the rate of base pairing errors
and contribute to this instability. In eukaryote cells, high-fidelity DNA
replication is accomplished by three DNA polymerases, POL alfa, POL
epsilon and POL delta (Lujan et al., 2016), and post-replicative mis-
match repair (MMR) (Kunkel, 2004). MMR germline defects have been
known for 25 years to be one of the causes of genetic predisposition to
CRC (Fishel et al., 1993), whereas pathogenic variants affecting the
proofreading activity of DNA replicative polymerases were very
recently associated with hereditary cancers (Palles et al., 2013).
POLE and POLD1 belong to the B family of replicative and repair
DNA polymerases. In DNA replication, they act as the major catalytic
and proofreading subunits of the POL epsilon and POL delta complexes,
respectively synthesizing the leading and lagging DNA strands (Nick
McElhinny et al., 2008). They have a proofreading function, performed
by their exonuclease domain, which detects and removes mis-
incorporated bases in the daughter strand through failed com-
plementary pairing with the parental strand (Miyabe et al., 2011). A
ternary structure of the catalytic core of POLE and POLD1 from Sac-
charomyces cerevisiae in complex with DNA and an incoming nucleotide
were recently solved (Hogg et al., 2014; Swan et al., 2009). These
structures can provide information about the selection of the correct
nucleotide and the positions of amino acids that might be critical for
proofreading activity and, therefore, it can be used to recognize po-
tentially pathogenic genetic variants.
Germline pathogenic variants in human POLE and POLD1 exonu-
clease domains have recently been reported to predispose to poly-
merase proofreading-associated polyposis (PPAP) (MIM# 615083 and
612591). This disease is characterized by multiple colorectal adenomas
and carcinomas following an autosomal dominant pattern of in-
heritance and suspected high penetrance. POLE p.Leu424Val and
POLD1 p.Ser478Asn were the first two variants found by performing
whole-genome sequencing in a small number of families with multiple
polyposis and CRC and then replicated detecting additional carriers by
genotyping 3,085 individuals from the UK with CRC (Palles et al.,
2013). This leading work prompted the directed screening of both genes
in subsequent familial CRC cohorts (Table 1).
Regarding associated phenotypes, pathogenic germline variants in
POLE and POLD1were initially implicated in genetic predisposition to
multiple polyposis and CRC (Palles et al., 2013). Later on, the pheno-
typic spectrum broadened to include other neoplasms such as en-
dometrial cancer (Church et al., 2013), ovarian and brain tumors
(Rohlin et al., 2014), pancreatic and small intestine cancer (Hansen
et al., 2015), melanoma (Aoude et al., 2015) or a clinical phenotype
suggestive of constitutional MMR deficiency (CMMRD) (Wimmer et al.,
2017). With regard to the clinical management of exonuclease mutation
carriers, Bellido et al. first proposed preliminary surveillance guidelines
based on the overlapping phenotype of this syndrome with attenuated
adenomatous polyposis (APC/MUTYH) and Lynch syndrome. The au-
thors adapted the Amsterdam and Bethesda criteria to the attenuated
polyposis scenario, taking into consideration additional specific POLE/
POLD1 characteristics such as the risk to endometrial cancer (Bellido
et al., 2016). In 2018, Buchanan et al., after estimating CRC risks for
POLE mutation carriers, recommended annual colonoscopy screening
and clinical management guidelines comparable to those currently
Table 1
Studies screening POLE and POLD1 among familial CRC cohorts.
POLE/POLD1 variants Study group Study methods References
POLE p.Leu424Val; POLD1 p.Leu474Pro 858 cases with familial and early-onset CRC or
polyposis
Direct genotyping or Sanger sequencing of
POLE/POLD1
Valle et al. (2014)
POLE p.Asn363Lys 1 large Swedish family with CRC and extra-
intestinal tumors
WES Rohlin et al. (2014)
POLE p.Leu424Val 266 unrelated German patients with polyposis
or familial CRC
Targeted sequencing of POLD1, POLD2, POLD3,
POLD4, POLE, POLE2, POLE3 and POLE4
Spier et al. (2015)
POLE p.Tyr458Phe 1 large Norwegian family with colorectal
adenomas and CRC, and extra-colonic cancers
WES Hansen et al. (2015)
POLE p.Leu424Val; POLD1 p.Asp316His,
p.Asp316Gly, p.Arg409Trp, p.Leu474Pro
441 nonpolyposis familial CRC and 88 polyposis
cases
Pooled DNA amplification and POLE/POLD1
targeted sequencing
Bellido et al. (2016)
POLE p.Trp347Cys 34 melanoma families WES Aoude et al. (2015)
POLE p.Lys425Arg 76 patients with CRC and/or polyposis Sanger Sequencing of POLE Rohlin et al. (2016)
POLE p.Val411Leu 14-year-old patient with polyposis and CRC Sanger sequencing of POLE/POLD1 Wimmer et al. (2017)
POLE p.Val474Ile 155 patients with multiple polyps or early-onset
CRC phenotype
Sanger sequencing of POLE/POLD1 Esteban-Jurado et al.
(2017)
POLE p.Asp275Val 274 Norwegian and Australian familial CRC Multi-gene panel Hansen et al. (2017)
Abbreviations: CRC, colorectal cancer; WES, whole-exome sequencing.
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recommended for Lynch syndrome or familial adenomatous polyposis
(Buchanan et al., 2018).
Outside cancer predisposition, pathogenic germline variants in
POLE (homozygous c.4444+3A>G, skipping of exon 34) have also
been involved in autosomal recessive predisposition to FILS syndrome,
characterized by mild facial dysmorphism, mainly malar hypoplasia,
livedo on the skin since birth, immunodeficiency resulting in recurrent
infections, and short stature (Pachlopnik Schmid et al., 2012). Ad-
ditionally, a pathogenic germline variant in POLD1, c.1812_1814delCT
(p.Ser605del), has been linked in an autosomal dominant manner to
germline predisposition to a multisystem disorder that includes sub-
cutaneous lipodystrophy, deafness, mandibular hypoplasia and hypo-
gonadism in males (Weedon et al., 2013), and also to Werner syndrome
(heterozygous c.1812_1814delCTC (p.Ser605del) and c.1519C>T
(p.R507C)) (Lessel et al., 2015). The non-cancerous phenotypes are
caused by different variants than those leading to cancer.
As previously mentioned, high-fidelity DNA replication is accom-
plished by DNA polymerases, including POLE and POLD1, and post-
replicative MMR. Indeed, POLD1 participates in the MMR system
(Longley et al., 1997). These two systems have been recently linked
regarding germline predisposition to CRC. The first POLE and POLD1
alterations in human disease were precisely detected in MMR-defective
CRC cell lines and tumors (Yoshida et al., 2011), implying that defective
polymerase proofreading in concert with MMR deficiency could con-
tribute to a cancer mutator phenotype. More recently, this relationship
has been exemplified by the detection of concomitant germline POLE
pathogenic variant and MMR somatic alterations in suggestive Lynch
syndrome cases with loss of expression of MMR proteins (Elsayed et al.,
2015; Jansen et al., 2016).
Besides their contribution to hereditary CRC, POLE and POLD1 can
also be somatically mutated. Tumor pathogenic variants in the POLE
exonuclease domain have been identified in 1–2% of sporadic CRC and
in 7–12% of endometrial cancers, as well as in tumors of the brain,
pancreas, ovary, breast, stomach and uterus (Cancer Genome Atlas
Network, 2012; Church et al., 2013). The most common somatic POLE
variants are p.Pro286Arg and p.Val411Leu, but p.Ser297Phe,
p.Ala456Pro and p.Ser459Phe have also been detected. On the other
hand, somatic POLD1 pathogenic variants seem to be much unusual in
CRC. Regarding their timing in oncogenesis, POLE pathogenic variants
are detectable in non-malignant precursor lesions of endometrial and
CRC, indicating that they are early, quite possibly initiating, events
(Temko et al., 2018). Carrying an alteration in replicative DNA poly-
merases increases the rate of base pairing errors. This fact is displayed
in the tumors of germline and sporadic POLE mutated carriers as an
ultramutated signature. This profile mainly involves base substitutions
and not copy-number alterations, and produces a 100-fold increase in
C-to-A transversions in the context of TCT and a 30-fold increase in C-
to-T transitions in the context TCG (Alexandrov et al., 2013). The tumor
mutational profile for POLD1 alterations is believed to also involve
ultramutation but is currently unknown. Cancer immunotherapy at-
tempts to stimulate the immune system to destroy tumors by using
immune checkpoint inhibitors that target immunosuppressive mole-
cules such as PD1 and PDL1. High tumor mutation burden is a pre-
dictive marker for immunotherapy response. Hypermutated tumors
show higher neo-antigen load and higher immunogenicity (Giannakis
et al., 2016). MMR deficient, microsatellite-unstable and POLE-mutated
tumors are good responders and show excellent prognosis (Domingo
et al., 2016).
Finally, it is important to highlight the need to correctly assess the
functional impact of POLE and POLD1 genetic variants. Nowadays,
next-generation sequencing projects easily identify genetic variation
but it is extremely important to distinguish among causative, non-
polymorphic germline variants, and somatic pathogenic, non-passenger
variants with prognosis meaning. Several efforts have already char-
acterized the functional effect of POLE variants in human cell-free as-
says (Shinbrot et al., 2014) and yeast (Barbari et al., 2018).
2.2. NTHL1-associated polyposis
After the identification of dominant germline pathogenic mutations
in the adenomatous polyposis coli gene (APC) as a cause for familial
adenomatous polyposis (MIM# 175100), many studies aimed to iden-
tify additional novel high-penetrant genes as cause for polyposis. The
subsequent identification of recessive pathogenic variants in MUTYH as
cause for polyposis and CRC (MIM# 608456), put the base-excision
repair (BER) pathway in the spotlight for a role in cancer predisposition
(Al-Tassan et al., 2002). Several studies performed candidate gene ap-
proaches to assess the occurrence of variants in multiple genes involved
in the BER in polyposis and CRC (Broderick et al., 2006; Dallosso et al.,
2008; Mur et al., 2018b; Smith et al., 2013b), but besides the identifi-
cation of MUTYH, none of the other BER genes revealed a clear role in
polyposis and CRC. However, in a recent whole-exome sequencing
(WES) study, in which a stringently selected cohort of 51 cases who
developed multiple adenomatous polyps at an early age in life were
investigated, led to the identification of NTHL1, another BER gene, as a
predisposing gene for polyposis and CRC (MIM# 616415) (Weren et al.,
2015a). WES revealed that four individuals from three independent
families carried a homozygous nonsense variant in NTHL1 in their
germline. Subsequent analyses of family members revealed complete
co-segregation with the adenomatous polyposis phenotype. Moreover,
six of the seven carriers of biallelic germline NTHL1 pathogenic variants
developed (multiple) tumors, including CRC and endometrial cancer
(Weren et al., 2015a).
Since its discovery, several additional cases with biallelic germline
mutations in NTHL1 have been published (Belhadj et al., 2017;
Broderick et al., 2017; Fostira et al., 2018; Rivera et al., 2015). In a very
recent international study, 11 additional families with biallelic germ-
line NTHL1 nonsense variants are described (Grolleman et al., 2019).
Whereas the initial families all carried a homozygous nonsense variant,
p.Gln90*, recent literature also revealed cases with compound hetero-
zygous pathogenic variants (all variants caused protein truncation of
NTHL1). Collectively, up to now 32 cases from 20 families with NTHL1
deficiency have been reported. All patients that underwent a colono-
scopy thus far (28 out of 32 cases) are described to have developed
adenomatous polyposis and CRC, albeit that this may be the cause of
inclusion bias. In addition, the majority of cases also presented with
multiple extracolonic malignancies (Belhadj et al., 2017; Broderick
et al., 2017; Fostira et al., 2018; Grolleman et al., 2019; Rivera et al.,
2015; Weren et al., 2015a). Together, these data confirm that defi-
ciency of NTHL1 causes polyposis and CRC, but also a tumor phenotype
that is different (14 different tumor types reported so far) than what is
known for MUTYH-associated polyposis (Win et al., 2016), including
high risk of breast cancer (Grolleman et al., 2019). Grolleman et al.
suggested that the established surveillance guidelines for MAP should
be extended to biallelic NTHL1 mutation carriers, starting colo-
noscopies at 18–20 years of age. Furthermore, breast cancer screening,
based on moderate risk, is advised. For the other cancers no surveil-
lance advices are currently described, due to uncertain cumulative
cancer risks and/or adequate screening methods. However, endometrial
cancer screening comparable with Lynch syndrome could be considered
(Grolleman et al., 2019). Additional studies are needed to determine
more precise cancer risk estimates and subsequently surveillance
guidelines for biallelic NTHL1 mutation carriers. Previous literature
suggested the prevalence of MUTYH-associated polyposis to be
1:5,000–40,000 (Aretz et al., 2013). Recently, Weren et al. (2018) es-
timated the incidence of MUTYH-associated polyposis to be 1:19,079 in
European individuals, based on the publically available Exome Ag-
gregation Consortium (ExAC) database. Similarly, Weren et al. esti-
mated that, based on protein truncation alleles of NTHL1 in the ExAC
database, the prevalence of NTHL1-associated tumor syndrome in the
European population to be 1:114,770 (Weren et al., 2018). This data
indicates that NTHL1-associated tumor syndrome is at least five times
as rare as MUTYH-associated polyposis. The prevalence of pathogenic
L. Valle, et al. Molecular Aspects of Medicine 69 (2019) 10–26
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alleles in NTHL1, such as the p.Gln90* allele, may vary between po-
pulations, which may explain why pathogenic variants in NTHL1 were
not identified previously (Broderick et al., 2006; Dallosso et al., 2008;
Smith et al., 2013b; Viel et al., 2017).
The BER machinery is involved in the repair of base lesions, which
can be caused by oxidative damage, alkylation or deamination. Tumors
derived from MUTYH-associated polyposis patients have revealed so-
matic variants that have a strong bias towards C>A transversions.
Mutational signature analyses (reviewed in more detail in chapter 6)
has shown that C>A transversions caused by deficiency of MUTYH
occur mainly in a NpCpA or NpCpT context (Pilati et al., 2017; Viel
et al., 2017). Tumors derived from patients with NTHL1-associated
tumor syndrome revealed a strong bias towards C>T transitions
(Rivera et al., 2015; Weren et al., 2015a). A study in which NTHL1 was
knocked out in human intestinal organoids revealed that these C>T
transitions mainly occur in a non-CpG context and that NTHL1 defi-
ciency is the mutational process underlying signature 30 (Drost et al.,
2017). By sequencing of CRCs and multiple extracolonic tumors from
carriers of biallelic germline NTHL1 pathogenic variants, Grolleman
et al. showed that the absence of functional NTHL1 has likely driven
formation of tumors in these patients, thereby confirming that defi-
ciency of NTHL1 causes a multi tumor predisposition syndrome
(Grolleman et al., 2019).
Signature 30 was originally identified in single breast cancer sample
that, upon retrospective analysis of the sequencing data, revealed a
heterozygous nonsense variant in NTHL1 in the germline and sub-
sequent NTHL1 deficiency in the breast cancer due to somatic loss of
the wild-type NTHL1 allele (Drost et al., 2017; Nik-Zainal et al., 2016).
Whether carriers of a heterozygous germline NTHL1 pathogenic variant
have an increased cancer risk, like has been observed for monoallelic
MUTYH carriers (Win et al., 2011), remains to be elucidated once more
mutation carriers have been identified.
2.3. Germline biallelic inactivation of MMR genes as cause of adenomatous
polyposis
Biallelic germline pathogenic variants in four MMR genes, MLH1,
MSH2, MSH6, and PMS2, result in a rare, inherited cancer predisposi-
tion syndrome named constitutional MMR deficiency syndrome
(CMMRD, MIM#276300). Individuals with CMMRD have a high risk of
developing a diverse spectrum of malignancies already in childhood
and adolescence. Approximately 80% of patients develop their first
malignancy before the age of 18 years. The spectrum includes mainly T-
cell non-Hodgkin lymphomas, high-grade gliomas and gastrointestinal,
mainly colorectal tumors. The majority of the CMMRD patients show
features typical of neurofibromatosis type I (NF1), particularly multiple
café au lait spots (Bakry et al., 2014; Wimmer and Etzler, 2008).
Remarkably, a large proportion of CMMRD patients develop mul-
tiple synchronous adenomas ranging from a few up to>100 polyps,
mimicking attenuated familial adenomatous polyposis (Aronson et al.,
2016; Jasperson et al., 2011; Levi et al., 2015; Toledano et al., 2009).
Adenomas of the colon and rectum were reported in 52 (36%) of the
patients, with a median age of 14 (range of first diagnosis between 6
and 46) (Wimmer et al., 2014). Most (35/52) of them showed high-
grade dysplasia or had synchronous bowel cancer (Wimmer et al.,
2014). Polyps in CMMRD can also resemble histologically to juvenile
polyposis (Levi et al., 2015). Gastrointestinal manifestations are highly
dependent on age of examination. All patients will have polyposis by
the third decade of life (Aronson et al., 2016).
Duodenal adenomas are found in 5% of CMMR-D cases, carcinoma
of the duodenal papilla, and gastric polyps have also been reported
(Herkert et al., 2011; Levi et al., 2015; Wimmer et al., 2014). Therefore,
as recommended by the care for MMRD consortium, CMMRD syndrome
should be considered as a differential diagnosis in patients under the
age of 25 years with multiple adenomas and absence of an APC/MUTYH
pathogenic variant and/or one adenoma with high-grade dysplasia
under the age of 25 (Wimmer et al., 2014). Genetic testing for the
presence of biallelic mutations in one of the four MMR genes is re-
commended to genetically confirm the diagnosis of CMMRD. When
gene testing is not possible or yields unclear results, other tests, such as
immunohistochemistry (IHC) revealing loss of the corresponding MMR
proteins or MSI can be used. Due to reports of colonic polyps as early as
6 years of age, guidelines recommend ileo-colonoscopies, upper endo-
scopy and video capsule endoscopy (VCE), at least yearly from a young
age, starting annual colonoscopies at 4–8 years, and small bowel sur-
veillance from age 8–10 years (Durno et al., 2017; Tabori et al., 2017;
Vasen et al., 2014). Preventive colectomy is recommended on the basis
of the degree of dysplasia and numbers of polyps observed during en-
doscopies (Tabori et al., 2017).
In 2016, Adam et al. reported the presence of biallelic pathogenic
variants in MSH3, an MMR gene not associated with Lynch syndrome,
in adenomatous polyposis patients without mutations in known poly-
posis predisposing genes. The associated phenotype was characterized
by the presence of colorectal adenomatous polyposis, diagnosed at their
thirties in most cases, accompanied by additional benign and malignant
lesions in the gastrointestinal tract and extracolonic. The phenotype
observed in MSH3 biallelic carriers largely resemble that of attenuated
familial adenomatous polyposis, although still conserving some features
of CMMRD occurring at more advanced age (not in the childhood)
(Adam et al., 2016).
Similar to MSH3, a recent publication by Olkinuora et al. showed
that a biallelic MLH3 truncating variant, c.3563C>G (p.Ser1188*),
founder in the studied Finnish population, causes classical or atte-
nuated adenomatous polyposis and possibly extracolonic tumors, in-
cluding breast cancer (Olkinuora et al., 2018).
2.4. GREM1-associated mixed polyposis
Hereditary mixed polyposis syndrome (HMPS1; MIM# 601228)
originally was described in an large Ashkenazi Jewish (AJ) family
whose members had multiple polyps of more than 1 histologic type
(adenomas, hyperplastic, and juvenile), and/or individual polyps with
overlapping histologic features (atypical juvenile with admixed histo-
logic features) (Jaeger et al., 2012; Rozen et al., 2003; Thomas et al.,
1996; Whitelaw et al., 1997). The underlying cause was a 40-kb du-
plication upstream of GREM1 at chromosome
15:30,752,231–30,792,051 (hg19), associated with an increased allele-
specific ectopic expression of GREM1 in the colon mucosa (Jaeger et al.,
2012). Overexpression of GREM1 suppresses BMP (Jaeger et al., 2012),
allowing epithelial cells retain stem cell-like properties, form ectopic
crypts and ultimately become neoplastic (Davis et al., 2015) Additional
reported cases of GREM1 duplications include a family with a 16-kb
duplication in the regulatory region (Rohlin et al., 2016), a patient with
polyps and family history of CRC who carried a 24 kb duplication of the
5′ regulatory region (McKenna et al., 2019), a patient with early onset
CRC with a large duplication encompassing the entire GREM1 gene
(Lieberman et al., 2012) and more AJ families with the 40-kb dupli-
cation (Davis et al., 2015; Laitman et al., 2015; Lieberman et al., 2017).
The 40-kb duplication has been detected among 1:184 AJ with personal
or family history of polyposis or CRC (Lieberman et al., 2017).
Polyposis is the prominent feature in HMPS1. In most HMPS1 fa-
milies, ages at onset of polyps are in the late 20s or older, however,
polyps at ages of 10, 16, and 18 have also been reported. Overlap of
GREM1 associated HMPS, familial adenomatous polyposis (FAP) and
Lynch syndrome, and extracolonic tumors have been reported
(Lieberman et al., 2017). Given the paucity of published descriptions of
GREM1-associated HMPS, management of affected families is challen-
ging. Current National Comprehensive Cancer Network recommenda-
tions for GREM1 carriers are to begin colonoscopies at ages 25–30,
repeated at 2- to 3-year intervals (1–2 years if polyps are detected)
(NCCN, 2017). However, reports of polyp onset in the adolescence and
rapid polyp progression to carcinoma (Lieberman et al., 2017; Rozen
L. Valle, et al. Molecular Aspects of Medicine 69 (2019) 10–26
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et al., 2003), suggest earlier colonoscopy screening initiation.
Though the GREM1 5′ regulatory region is now analyzed on many
different multi-gene cancer panels, CNVs of regulatory regions are not
typically analyzed in NGS data, thus, could be easily missed.
2.5. RNF43-associated serrated polyposis
Serrated polyps are considered the precursor lesions of up to
15–30% of all colorectal carcinomas through the serrated pathway,
molecularly characterized by the presence of somatic pathogenic var-
iants in BRAF, hypermethylation of the promoter regions of tumor
suppressor genes and microsatellite instability (Leggett and Whitehall,
2010; Snover, 2011). Serrated polyps are comprised by a heterogeneous
group of lesions morphologically characterized by serrated (saw-tooth)
architecture of the epithelium that lines the colonic crypts, and which
include: hyperplastic polyps, sessile serrated adenomas/polyps, and
traditional serrated adenomas/polyps (Rex et al., 2012).
The serrated polyposis syndrome (SPS; MIM# 617108) is a hetero-
geneous disease defined by the presence of multiple serrated polyps
throughout the colon, causing an increased risk (16%) of CRC (Carballal
et al., 2016). The clinical definition of SPS is based on the fulfilment of
one of the revised World Health Organization (WHO) criteria: i) at least
5 serrated polyps proximal to the sigmoid colon, two of them larger
than 10mm; ii) any number of serrated polyps proximal to the sigmoid
colon in an individual with one first-degree relative with SPS; or iii)
more than 20 serrated polyps distributed throughout the colon (Snover
et al., 2010). Only 10–50% of SPS patients report a family history of
CRC (Boparai et al., 2010; Chow et al., 2006; Kalady et al., 2011; Lage
et al., 2004; Navarro et al., 2013; Oquinena et al., 2013; Rubio et al.,
2006). Being this entity mostly sporadic, -diagnosed between 50 and 60
years of age and believed to be strongly associated with environmental
factors (Buchanan et al., 2010; JE et al., 2016; JE et al., 2017)-, it has
been suggested that, overall, SPS is not an inherited genetic syndrome
but rather behaves as a complex disorder consequence of the interac-
tion of genetic susceptibility and environment. However, evidence in-
dicates that a small proportion of cases may be due to an inherited
genetic syndrome.
In 2014, by performing WES in 20 SPS families, Gala et al. identified
in two independent families a germline deleterious variant, c.337C>T
(p.Arg113*), in the RING-type E3 ubiquitin ligase RNF43 -inhibitor of
the Wnt pathway- (Gala et al., 2014). Moreover, knock out of RNF43
contributes to an intestinal polyposis phenotype in mice (Koo et al.,
2012). Taupin et al. identified the RNF34 c.394C>T (p.Arg132*)
variant in two SPS-affected members of one family (Taupin et al.,
2015), and Yan et al., by performing whole-exome sequence analysis of
4 SPS families, identified a deleterious germline variant, c.953-1G>A
(p.Glu318fs), in 6 members of one family, 5 fulfilling the revised WHO
criteria (Yan et al., 2017). Buchanan et al. assessed the mutation status
of RNF43 in 74 selected SPS families, identifying two rare missense
variants, c.443C>G (p.Ala148Gly) and c.640C>G (p.Leu214Val), in
two families (Buchanan et al., 2017). Theses variants were predicted
deleterious by in silico algorithms and later demonstrated to diminish
the inhibitory effect of RNF43 on Wnt signaling (Quintana et al., 2018).
No carriers of p.Arg113* or p.Arg132* were detected in 221 additional
SPS patients (Buchanan et al., 2017). Recently, Quintana et al. studied
RNF43 mutation status in 96 serrated polyposis patients, identifying
one carrier of the p.Arg132* variant in a woman diagnosed with CRC
and>50 polyps (including serrated lesions) (Quintana et al., 2018).
Up to date, a total of 13 carriers (7 families) of RNF43 (likely) pa-
thogenic variants have been reported, 12 of who are affected with
serrated polyposis and/or CRC (mean age at diagnosis: 44; range:
18–65). All colonic lesions analyzed showed RNF43 somatic loss or
mutation (23/23), and 50% (9/18) had the CpG island methylator
phenotype (CIMP), a common feature of the serrated pathway. Table 2
depicts the clinical and molecular features of the reported carriers of
RNF43 (likely) pathogenic variants.
The scarce available data suggests that this is an extremely rare
syndrome, apparently associated with a high risk to develop serrated
polyps and absence of extracolonic manifestations. Nevertheless, data
from additional carriers are required to estimate prevalence and pe-
netrance, and accordingly recommend gene-specific surveillance.
2.6. RPS20 mutations as a rare cause of hereditary nonpolyposis CRC
Despite the enormous efforts made for the identification of new
genes that could explain the apparently dominantly inherited forms of
MMR-proficient nonpolyposis CRC in the last decades, RPS20, which
encodes a component (S20) of the small ribosomal subunit, is the only
candidate gene that has shown consistent association with hereditary
nonpolyposis CRC (Valle, 2017). By combining genetic linkage analysis
and WES, Nieminen et al. identified a novel truncating RPS20 variant,
c.147dupA (p.Val50Serfs*23), in a Finnish four-generation CRC-af-
fected family. The variant was present in 7 CRC-affected members but
neither in 4 cancer-free members nor in one relative diagnosed with
breast cancer at age 55. All studied tumors were MMR proficient and
did not show loss of the RPS20 wildtype allele, arguing against the
traditional 2-hit mechanism of inactivation of tumor suppressor genes.
Patients carrying the RPS20 c.147dupA variant showed a marked in-
crease of 21S pre-rRNAs, supporting a late pre-rRNA processing defect
consistent with haploinsufficiency. No additional RPS20 (likely) pa-
thogenic variants were identified in 25 Finnish MMR-proficient Am-
sterdam-positive families and in 61 primary CRCs and cancer cell lines
(Nieminen et al., 2014).
Broderick et al. analyzed whole-exome/genome sequencing data
from 863 early-onset/familial CRC cases and 1,604 individuals without
CRC, and identified a truncating RPS20 variant, p.Leu61Glufs*11, in a
39 year-old individual with metachronous CRC. They also identified a
missense variant, p.Val54Leu, predicted pathogenic, in a 41-year-old
CRC patient who fulfilled the Amsterdam criteria for hereditary CRC.
No rare missense/disruptive RPS20 variants were detected in the 1,604
controls (Broderick et al., 2017). So far, only the three CRC families
discussed above have been reported to carry RSP20 (likely) pathogenic
variants. Although the scarce available data suggests low prevalence
and high penetrance for RSP20 pathogenic variants, as well as absence
of extracolonic manifestations, data from additional carriers are re-
quired to estimate risks and recommend gene-specific surveillance
measures.
3. Pathogenic variants in other hereditary (non-CRC) cancer genes
CRC is common, specifically in the Western world, and it is there-
fore not unexpected to find CRC in families with a high burden of
cancer. Further, CRC has been observed in families harboring a germ-
line (likely) pathogenic variant in genes not generally associated with
CRC. However, there has been conflicting evidence regarding the CRC
causality of non-CRC cancer genes. BRCA1 and BRCA2, which are as-
sociated with hereditary breast and ovarian cancer (HBOC; MIM#
604370 and 612555), are the most studied genes in this context, and
some of the studies are summed up in Table 3. The debate about
whether pathogenic BRCA variants increase the risk of CRC is still on-
going (Esteban-Jurado et al., 2016; Garre et al., 2015; Kadouri et al.,
2007; Kirchhoff et al., 2004; Niell et al., 2004; Phelan et al., 2014; van
Asperen et al., 2005). As an example, Garre et al. published evidence of
an association between a germline BRCA2 pathogenic variant and CRC
risk. They performed mutation screening of BRCA2 in 48 probands from
families with a dominant inheritance pattern of CRC, but without al-
terations in any of the known CRC susceptibility genes. The frameshift
variant c.3847_3848delGT (p.Val1283Lysfs*2) was found to co-segre-
gate with CRC as well as to present loss of BRCA2 heterozygosity (LOH)
in CRC tumor DNA (Garre et al., 2015). Contrary, Phelan et al. con-
cluded that the risk of CRC is only increased in female carriers of
BRCA1 (likely) pathogenic variants below the age of 50 years, but not
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in women with BRCA2 variants or in older women. They followed 7,015
women with BRCA pathogenic variants for an average of 5.5 years and
found 21 new cases of CRC, whereof 8 were in BRCA1mutation carriers
below 50 years (Phelan et al., 2014). A recent meta-analysis based on
14 studies (Oh et al., 2018), validated some of the results from Phelan
et al., finding a potential 1.22-fold greater risk of CRC in BRCA pa-
thogenic variant carriers, and this was largely attributable to a 1.48-
fold greater risk in BRCA1 but not in BRCA2 carriers, regardless of age.
Due to variable design and conflicting evidence of causality in stu-
dies investigating the CRC risk in BRCA mutation carriers (Table 3)
(Sopik et al., 2015), there is still no consensus of whether to screen for
CRC in HBOC families. Another aspect to be discussed is whether CRC
patients with a pathogenic BRCA variant may benefit from treatments
used in HBOC (Soyano et al., 2018).
Due to next generation sequencing (NGS) and the increasing use of
multigene panel testing and WES, pathogenic variants in other non-CRC
hereditary cancer genes have been described recently in familial CRC,
pointing to their association with CRC susceptibility (Table 4). Most of
these genes have not yet been studied to the same extent as the BRCA
genes. However, in some cases, such as for carriers of PTEN pathogenic
variants, CRC screening has been recommended already in the clinical
guidelines (Syngal et al., 2015). PTEN is associated with Cowden Syn-
drome, which is a hamartomatous disorder with an increased risk for
the development of breast, thyroid and endometrial carcinomas (MIM#
158350). During the last years, hyperplastic, adenomatous and other
types of polyps have been described in the colon epithelium of carrier of
PTEN pathogenic variants, indicating an increased risk for CRC (Stanich
et al., 2014). The tumor suppressor genes TP53 and CHEK2 may also
predispose to CRC (Pearlman et al., 2017; Rosenthal et al., 2017;
Yurgelun et al., 2017; Yurgelun et al., 2015a,b). TP53 germline muta-
tions are associated with Li-Fraumeni syndrome (LFS; MIM# 151623),
which predisposes to a wide range of cancers that originally did not
include CRC. A TP53 splice site variant c.783-1G>A, was detected in
an atypical family fulfilling both the Chompret criteria for LFS and the
Amsterdam II criteria for hereditary non-polyposis CRC (Martin-
Morales et al., 2018). Several TP53 pathogenic variants have been de-
tected in familial or early-onset CRC cases (Rosenthal et al., 2017;
Yurgelun et al., 2017; Yurgelun et al., 2015a,b), suggesting an increased
CRC risk in LFS families. For this reason, CRC screening is now re-
commended in LFS families (Kratz et al., 2017). CHEK2 missense var-
iants c.470T>C (p.Ile157Thr) and c.349A>G (p.Arg117Gly), which
are involved in breast and pancreatic cancer predisposition, have also
been reported to be associated with CRC (Kilpivaara et al., 2006;
Martin-Morales et al., 2018).
Variants in other HBOC genes have been detected in familial CRC.
Pathogenic variants in the Fanconi Anemia gene BRIP1, associated with
a higher risk of ovarian cancer (Rafnar et al., 2011), have been reported
recently in familial CRC (Esteban-Jurado et al., 2015; Martin-Morales
et al., 2018; Yurgelun et al., 2015a). Mutated BRCA1-associated gene
BARD1, has been also found in a CRC family (Esteban-Jurado et al.,
2015). Moreover, ATM and PALB2 have been connected to CRC risk
(AlDubayan et al., 2018; Pearlman et al., 2017; Yurgelun et al., 2017).
AlDubayan et al. showed significant enrichment of germline pathogenic
variants in ATM and PALB2 in CRC individuals compared to cancer-free
individuals. In this study, five out of 680 unselected CRC individuals
had pathogenic variants in ATM whereas three individuals had germ-
line pathogenic variants in PALB2. The five individuals with variants in
ATM had evidence of somatic inactivation of the wild-type allele (LOH
or truncating variant) in tumor samples whereas no somatic inactiva-
tion was detected in any of the tumors in individuals with germline
PALB2 pathogenic variants (by WES). Seemingly, the basis for tumor
initiation and/or progression could be different between these two
genes even though they both belong to the HR (homologous re-
combination) pathway (AlDubayan et al., 2018).
Another non-CRC cancer gene that has been reported in a CRC
context is CDNK2A (Lynch et al., 2002; Pearlman et al., 2017; Yurgelun
et al., 2017). Pathogenic variants in CDKN2A are associated with fa-
milial atypical mole melanoma syndrome (FAMMM; MIM# 606719)
and are known to predispose to melanoma and pancreatic cancer.
Lynch et al. (2002) studied eight FAMMM families with CDKN2A
germline pathogenic variants. Although there were four cases of CRC in
three of these families, there was no information on whether the in-
dividuals affected with CRC were carriers of CDK2A pathogenic var-
iants (two splice-site and one missense variant). Two of these CRCs
were of late onset (age of onset not given for the other two) and may
therefore represent sporadic cases (Lynch et al., 2002). Pearlman et al.
identified one out of 450 CRC patients younger than 50 years with a
CDKN2A pathogenic variant, and Yurgelun et al. detected the same
CDKN2A pathogenic variant (c.9_32dup) in one out of 1,058 unselected
CRC patients (Pearlman et al., 2017; Yurgelun et al., 2017). Other genes
implicated in rare syndromes that predispose to various kinds of cancer
(such as thyroid, renal and pancreatic) have also been detected in
hereditary CRC, including CDKN1B, SMARCA4 (Esteban-Jurado et al.,
2015) and XPC (Martin-Morales et al., 2018).
In summary, recent studies increasingly report the implication of
non-CRC cancer predisposing genes in hereditary CRC. However, the
evidence for an increased risk of CRC is not established for most of these
genes and must be further studied, to conclude if CRC surveillance
should be included in the management of mutation carriers. Although
the contribution of pathogenic variants in non-CRC cancer genes to the
heredity of CRC is limited compared to the classical CRC genes, it is still
relevant. The above studies show a substantial phenotypic overlap
among different hereditary cancer syndromes. This observation has
raised some concerns suggesting that phenotype-directed genetic
testing may sometimes be incomplete. However, the current testing
strategy for inherited cancers is moving from single genes towards
multigene panel testing, covering the most common hereditary cancer
genes.
4. Identification of causal genes
Familial clustering of cancer is caused by genetic and shared en-
vironmental factors. However, when environmental factors were as-
sessed between spouses, i.e., when environmental sharing starts in
adulthood, even long-term co-habitation appeared to influence only a
few cancers, lung, upper aerodigestive tract and skin cancers, and the
relative risks were far below the ones known for familial risk at these
sites (Schmit et al., 2018; Weires et al., 2011). For colon cancer the
relative risk was 1.01 and for rectal cancer it was 0.91 (neither statis-
tically significant), probably surprisingly, in view of the collective belief
that diet is important in CRC. The spouse data suggest that genetic
sharing (i.e., heritability) is the most important contributor to familial
clustering (Frank et al., 2014; Frank et al., 2015). However, identified
genes and low-risk loci explain only a small proportion of heritability in
cancer (Sampson et al., 2015; Sud et al., 2017; Valle, 2017). For CRC,
known high-risk and low-risk genes are thought to account approxi-
mately equally, and jointly account for a quarter of familial clustering
(Sampson et al., 2015; Sud et al., 2017). In familial CRC the inherited
genes are enriched, and the estimates for high-risk genes vary between
17% and 28% depending on the definition of pathogenicity of the
variants (Chubb et al., 2016).
4.1. Cancer germline architecture
Until the millennium shift, linkage analysis was the main tool of
gene discovery (Rahman, 2014). Of the more than 100 known cancer
predisposing genes most were detected using the linkage approach in
Mendelian types of families. Most of the 10 high-risk genes predisposing
to CRC were also found using such approaches (Turnbull et al., 2018).
With the success of this approach fading, many scientists propagated
instead for an association study approach based on a paradigm that
common diseases, such as cancer, would be caused by common
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variants, the ‘common disease-common variant’ hypothesis. The fa-
milial risk conveyed by such variants would be small, which would
imply non-Mendelian genetics. By today, such genome-wide association
studies (GWASs) have delivered some 600 genomic loci at genome-wide
significance, and considering CRC alone, 50 loci have been validated,
accounting for ∼12% of familial risk of CRC (Nieminen et al., 2014;
Schmit et al., 2018). As the risks are low, the clinical utility of the
developed ‘polygenic risk scores’ are debated. Moreover, the newly
reported risks of single variants have become very small and views are
being expressed that the GWAS era is approaching its end. The GWAS
era demonstrated that familial cancers may share a monogenic/oligo-
genic and a polygenic background which is dependent on cancer type;
for CRC the monogenic and polygenic architectures appear equally
common, in contrast to some rare cancers and even ovarian cancer,
dominated by the monogenic background, and prostate and lung
cancer, dominated by the polygenic background.
By now, whole-exome and whole-genome sequencing approaches
have revolutionized oncogenomics and have made it an integral part of
precision cancer care. However, the main success has been in somatic
genetics (tumors) while successes in germline genetics have been lim-
ited, including CRC and most other cancers. The successful reports on
gene identification for CRC include POLE, POLD1, NTLH1,MSH3,MLH3
and RPS20 pathogenic variants in familial CRC and polyposis (Adam
et al., 2016; Nieminen et al., 2014; Olkinuora et al., 2018; Palles et al.,
2013; Weren et al., 2015a). One reason for success of these studies was
the inclusion of families, whereas even large studies on individual fa-
milial cases did not produce novel predisposing genes, but have yielded
important population estimates on variant frequencies (Chubb et al.,
2016).
Information on germline genetic architecture is a relevant guidance
to gene identification studies and the methods to be applied. High-risk
genes (i.e., relative risk of the order of 10 or more) would cause
Mendelian type of clustering with many affected family members over
generations. In the Swedish population of 10 million individuals,
29,000 CRCs were diagnosed in one generation, and 3,800 (13.2%)
patients had a family history of CRC in parents or siblings; among these
only 220 (0.8% of all CRC, 6% of familial CRC) had two or more af-
fected family members which would be suggestive of high-penetrance
clustering (Frank et al., 2015). This can be put to a perspective as a
recent study reported that 369 Lynch syndrome families were identified
in Sweden (Lagerstedt-Robinson et al., 2016). However, these figures
are not fully comparable because it is likely that many Lynch syndrome
families were identified in an older generation not covered by the above
Swedish population data, resulting in 220 high risk families. Yet, the
numbers help to delineate the scope of finding novel high-risk CRC
genes, which may be limited to extremely rare, perhaps even private
pathogenic variants, as has been discussed by others (Turnbull et al.,
2018).
4.2. Family based approach and tools
The best approach in search of high-risk genes is to use families.
Horn et al., by using the linkage approach, identified a TERT promoter
mutation in a single large melanoma family. Although promoter mu-
tations in TERT are now well known as common somatic drivers in
many cancers, only a total of three melanoma families world-wide are
known carrying the germline mutation. A contributing factor for se-
lecting this family, in addition to the large numbers of cases amenable
to linkage analysis, was that the phenotype was rather unique with
early onset and aggressive course (Horn et al., 2013).
The availability of cancer pedigree samples, including also appar-
ently healthy family members is an advantage and needs to be appro-
priately analyzed. A familial cancer variant prioritization pipeline
(FCVPP) has been developed for detection of deleterious germline
variants with potential clinical importance in cancer predisposition
(Forsti et al., 2016; Kumar et al., 2018). As the first step, a segregation
function for families is included: the variants should be present in cases
and not in controls; this step may exclude more than 90% of the po-
tential variants. Likely functionality of the variant is defined by several
in silico tools, summarized as the CADD score and the variant has to be
rare in the European population which is tested by databases such as
GnomAD (Genome Aggregation Database; http://gnomad.
broadinstitute.org/). The pipeline then uses 12 tools for evaluation of
deleteriousness of missense variants and 5 tools for evaluation intol-
erance of the corresponding genes against functional variants. In as-
sessing non-coding regions the pipeline combines Miranda and Tar-
getscan for 3′ UTR variants and SNPnexus and ChromHMM for
detection of transcription binding sites and chromatin modification
patterns for 5′UTR variants. The pipeline combines FANTOM5 data and
SNPnexus for finding regulatory features of variants located in the en-
hancer and promoter regions. Genomic Evolutionary Rate Profiling and
PhastCons are used for the assessments of conservation across species at
the variant position. Ultra-sensitive and sensitive regions are assessed
by Funseq2 and ultra-conserved non-coding elements by UCNEbase. At
the end of the pipeline usually less than 10 candidate variants survive.
These are further assessed through cancer predisposition gene data-
bases, pathway analysis and literature search. The surviving candidates
need to be verified by Sanger sequencing and functionality need to be
demonstrated using appropriate in vitro tests.
In conclusion, whether the present pipeline leads to discovery of
novel cancer predisposition genes does not depend on the pipeline but
what is fed in, i.e., pedigree data. Maybe the assumption of a single
causal gene may not be correct for the family under study. The numbers
of true Mendelian cases increase the power of detection and it is as
critical as the correctness of diagnoses. A false assignment of a phe-
nocopy as a Mendelian case or mixing of individuals or samples may
have devastating consequences for the analysis. Last but not least, the
quality of sequence data and sufficient coverage are important.
5. Candidate genes for hereditary non-polyposis CRC and
polyposis
Genomic characterization of the germline DNA of patients with fa-
milial CRC has been performed in the last 30 years. Diverse meth-
odologies have been used ranging from classical linkage analysis in
large families to the more recent NGS approaches in several small fa-
milies. Remarkably, this later methodology has boosted the number of
candidate genes for hereditary predisposition to this neoplasm. Table 5
summarizes all previous studies proposing new candidate genes for
CRC, detected in non-affiliated familial and/or early onset cases for this
disease.
Sanger sequencing has been widely used in candidate gene ap-
proaches for the identification of germline pathogenic variants in CRC
(Coissieux et al., 2011; Guda et al., 2009; Lammi et al., 2004; Richards
et al., 1999; Sweet et al., 2005; Zogopoulos et al., 2008), however, most
findings have not been replicated in additional cohorts, so far. There is
nevertheless evidence in favor of the implication of the AXIN2 and ENG
genes in adenomatous and hamartomatous or hyperplasic mixed poly-
posis, respectively (Lammi et al., 2004; Marvin et al., 2011; Ngeow
et al., 2013; Rivera et al., 2014; Sweet et al., 2005).
GALTN12 has been proposed in several studies as a strong candidate
CRC susceptibility gene, given linkage and association studies, and in-
activating somatic and germline alleles in CRC patients (Clarke et al.,
2012; Gray-McGuire et al., 2010; Guda et al., 2009; Kemp et al., 2006;
Skoglund et al., 2006; Wiesner et al., 2003). However, GALTN12 does
not seem to be a major high-penetrance gene for CRC predisposition
(Lorca et al., 2017; Segui et al., 2014). Recently, Evans et al. defined
GALTN12 as a moderate penetrance gene for CRC (Evans et al., 2018).
With the advent of NGS technologies, numerous studies have
emerged to identify new genes of susceptibility to CRC by WES.
Initially, these studies did not validate their findings in additional in-
dependent cohorts and only proposed candidate genes with more or less
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evidence of causality for hereditary CRC. They just reported a detailed
list of rare (MAF≤1%) and loss-of-function candidate variants in genes
that had been selected according to either their role in CRC carcino-
genesis, potential implication as tumor suppressors, presence in ge-
netically enriched subsets of early-onset CRC cases, absence in healthy
controls, or cosegregation of the variants within the families (Brea-
Fernandez et al., 2017; Chubb et al., 2016; de Voer et al., 2016;
DeRycke et al., 2013; Esteban-Jurado et al., 2015, 2016; Gylfe et al.,
2013; Smith et al., 2013a; Spier et al., 2016; Tanskanen et al., 2015;
Thutkawkorapin et al., 2016; Yu et al., 2018).
The development of genome-wide copy number arrays and massive
parallel sequencing resulted in a shift of techniques used in the quest for
finding novel genes predisposing to CRC and polyposis. Where pre-
viously genome-wide linkage analysis and candidate gene approaches
were used, nowadays genome-wide copy number analyses (CNA), WES
and more recently whole-genome sequencing (WGS) are employed to
identify novel genes predisposing to CRC and polyposis. As these
genome-wide techniques are less time-consuming and less or equally
expensive, isolated cases and cases with a less clear familial history for
CRC are included in discovery and replication cohorts. These ap-
proaches have resulted in the identification of several novel high-pe-
netrant CRC and polyposis predisposing genes, such as POLE, POLD1
and NTHL1, but have also resulted in a compilation of candidate genes,
for which much more evidence is required before they can be im-
plemented in daily clinical genetics practice.
Variants in several components involved in the spindle assembly
checkpoint, which ensures proper chromosome segregation during
mitosis, are associated with CRC predisposition, such as BUB1B, BUB1
and BUB3 (de Voer et al., 2013; Mur et al., 2018a; Rio Frio et al., 2010).
BUB1B was identified in a single isolated case and has remained the
only case thus far, probably as a result from a unique homozygous
variant resulting in very low levels of BUBR1 (Hahn et al., 2016; Rio
Frio et al., 2010). Evidence from functional studies on BUB1 and BUB3
variants suggest pathogenicity for several variants (de Voer et al., 2013;
Mur et al., 2018a), while other studies do not find any association
(Broderick et al., 2017).
For several other candidate CRC and polyposis predisposing genes
indirect functional evidence on pathogenicity has been gathered, such
as WRN, ERCC6, SEMA4A, SMAD9, SEMA4A, FAN1, FOCAD, LRP6,
MSH3, SETD6 and BRF1 (Adam et al., 2016; Arora et al., 2015; Bellido
et al., 2018; de Voer et al., 2016; Martin-Morales et al., 2017; Ngeow
et al., 2015; Schulz et al., 2004; Segui et al., 2015; Weren et al., 2015b).
Several of these genes, such as WRN, ERCC6 and FAN1, play a role in
the DNA damage response, whereas others play a role in focal adhesion
(FOCAD), semaphorin signaling (SEMA4A), TGF-β signaling (SMAD9),
WNT signaling (LRP6 and SETD6), DNA MMR (MSH3), and transcrip-
tion initiation (BRF1).
Besides WES, other approaches have shed additional light into this
area. Targeted sequencing of previously selected genes has also been
applied to some extent yielding additional candidate genes (Hahn et al.,
2016; Hansen et al., 2017). A combination of homozygosity mapping,
linkage analysis and exome and whole-genome sequencing proposed
MIA3 as an additional candidate gene (Schubert et al., 2017). CNV
approaches to identify mutational events with a putative involvement
in CRC germline predisposition have also been explored (Brea-
Fernandez et al., 2017; Franch-Exposito et al., 2018).
In summary, it remains to be elucidated if the majority of these
candidate genes will play a role in predisposition to CRC and/or poly-
posis, which will likely be facilitated in the next decade once WES or
WGS is implemented in routine genetic diagnostics.
6. Conclusions
As other complex diseases, CRC is caused by both genetic and en-
vironmental factors. Twin studies showed that around 13%–30% of the
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that sense, a minority of CRC cases (∼5%) show strong familial ag-
gregation and belong to the well-known hereditary CRC forms, mainly
caused by germline pathogenic variants in known high-penetrance
hereditary genes such as APC, MUTYH and the DNA MMR genes.
Recently, NGS studies have identified new high-penetrance CRC her-
editary genes, and a large number of candidate genes that require
further evidence to be implemented in routine genetic testing. This
review described recent advances and new genes lately described to be
involved in hereditary CRC. For the newcomers in this scenario, it re-
mains to be elucidated if the majority of these candidate genes will play
a relevant role in predisposition to CRC and/or polyposis, which will be
likely facilitated in the next decade once WES or WGS are implemented
in routine genetic diagnostics.
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